Mena FN1d
Karyopharm To Present Selinexor Data At The 66Th American Society Of Hematology Annual Meeting And Exposition
"The data being presented demonstrate our commitment, as well as that of our partners to our ongoing work in multiple myeloma and myelofibrosis." ...
Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer ...
news.stv3d
Donor appeal: 'Thought that I might not be here for my daughter is terrifying'
Rachael Nixon desperately needs to find a stem cell donor, after being diagnosed with a rare and aggressive form of blood cancer.
Daily5d
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Pharmabiz5d
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Pharmaceutical Technology5d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
EurekAlert!6d
Sylvester Cancer researchers share findings in oral presentations at the ASH 2024 Annual Meeting & Exposition
Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained ...
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Schrödinger Reports Third Quarter 2024 Financial Results
Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...